[{"address1": "3020 Carrington Mill Blvd.", "address2": "Suite 475", "city": "Morrisville", "state": "NC", "zip": "27560", "country": "United States", "phone": "212 554 4484", "fax": "212 554 4531", "website": "https://www.tgtherapeutics.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.", "fullTimeEmployees": 264, "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael S. Weiss Esq.", "age": 57, "title": "Chairman, CEO & President", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 1968759, "exercisedValue": 0, "unexercisedValue": 5090000}, {"maxAge": 1, "name": "Mr. Sean A. Power CPA", "age": 41, "title": "CFO, Corporate Secretary & Treasurer", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 670578, "exercisedValue": 0, "unexercisedValue": 3031375}, {"maxAge": 1, "name": "Jenna  Bosco", "title": "Senior Vice President of Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam  Waldman", "title": "Chief Commercialization Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 10, "compensationRisk": 10, "shareHolderRightsRisk": 5, "overallRisk": 10, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 25.86, "open": 26.91, "dayLow": 26.15, "dayHigh": 27.67, "regularMarketPreviousClose": 25.86, "regularMarketOpen": 26.91, "regularMarketDayLow": 26.15, "regularMarketDayHigh": 27.67, "beta": 2.208, "forwardPE": 28.6, "volume": 4024013, "regularMarketVolume": 4024013, "averageVolume": 3581141, "averageVolume10days": 3600830, "averageDailyVolume10Day": 3600830, "bid": 27.05, "ask": 27.27, "bidSize": 200, "askSize": 500, "marketCap": 4206541056, "fiftyTwoWeekLow": 9.81, "fiftyTwoWeekHigh": 27.67, "priceToSalesTrailing12Months": 15.886329, "fiftyDayAverage": 23.5611, "twoHundredDayAverage": 18.73365, "currency": "USD", "enterpriseValue": 3793215744, "profitMargins": -0.054250002, "floatShares": 133474909, "sharesOutstanding": 154823008, "sharesShort": 32482915, "sharesShortPriorMonth": 29835522, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.20979999, "heldPercentInsiders": 0.09591, "heldPercentInstitutions": 0.61897, "shortRatio": 7.76, "shortPercentOfFloat": 0.2319, "bookValue": 1.238, "priceToBook": 21.946688, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "earningsQuarterlyGrowth": -0.966, "netIncomeToCommon": -14364000, "trailingEps": -0.11, "forwardEps": 0.95, "lastSplitFactor": "100:5625", "lastSplitDate": 1335744000, "enterpriseToRevenue": 14.325, "enterpriseToEbitda": -9251.746, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "TGTX", "underlyingSymbol": "TGTX", "shortName": "TG Therapeutics, Inc.", "longName": "TG Therapeutics, Inc.", "firstTradeDateEpochUtc": 1272893400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "d6673518-e04c-3ac1-8be7-75085ffff3ed", "gmtOffSetMilliseconds": -18000000, "currentPrice": 27.17, "targetHighPrice": 55.0, "targetLowPrice": 9.0, "targetMeanPrice": 38.13, "targetMedianPrice": 42.5, "recommendationMean": 2.1, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 217252000, "totalCashPerShare": 1.514, "ebitda": -410000, "totalDebt": 112919000, "totalRevenue": 264790000, "debtToEquity": 63.592, "revenuePerShare": 1.829, "earningsGrowth": -0.973, "revenueGrowth": -0.494, "grossMargins": 0.88315004, "ebitdaMargins": -0.00155, "operatingMargins": 0.14824, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-07"}]